Table 2

Reactivity of sera from HIV-1- or HIV-2-infected individuals and SIVmac251-infected rhesus macaques with therapeutic C peptides

C peptideSeroreactivitya
HIV-1HIV-2 (n = 10)SIVmac251 (n = 9)
ART (n = 35)No ART (n = 34)LTNP (n = 10)Anti-C46-EHO positive (n = 7)Anti-C46-EHO negativeb
C4621 (60.0)30 (88.2)8 (80.0)0 (0.0)0 (0.0)
C46-EHO3 (8.6)4 (11.8)1 (10.0)7 (100.0)0 (0.0)8 (80.0)7 (77.8)
V16 (85.7)5 (33.3)10 (100.0)ND
V24 (57.1)1* (5.0)10 (100.0)7 (77.8)
V37 (100.0)1 (6.7)8 (80.0)ND
V47 (100.0)4 (26.7)10 (100.0)ND
V2o0 (0.0)0 (0.0)10 (100.0)8 (88.9)
  • a Seroreactivity is shown as the number (percentage) of serum samples recognizing the respective C peptides in dot blot assays. ART, antiretroviral therapy; LTNP, long-term nonprogressor; ND, not determined.

  • b Fifteen serum samples were tested for all peptides, except as indicated (*), in which case 20 serum samples were tested for V2 reactivity. Anti-C46-EHO-negative samples were randomly chosen from the ART and no ART groups.